Latest OncoGenex Pharmaceuticals Inc. Stories

BOTHELL, WA and VANCOUVER, BC, Feb. 25 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with...

BOTHELL, WA and VANCOUVER, BC, Feb. 25 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company and Steve Anderson, its chief financial officer, have agreed that he will leave the Company effective yesterday. OncoGenex has initiated an executive search to identify a CFO candidate suited for the next stage of company growth, with deep ties in the biopharma investment community and experience transitioning a pharmaceutical company from R&D...

BOTHELL, WA and VANCOUVER, BC, Jan. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding. The funds were awarded by a third party granting agency to Dr. Kim Chi, a medical oncologist at the BC Cancer Agency, Research Scientist at the...

CARLSBAD, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced...

-- Phase III trials of OGX-011 in first- and second-line advanced prostate cancer and non-small cell lung cancer, expected to begin in 2010 and early 2011 -- -- Significantly strengthens Teva's oncology offerings with novel therapeutic designed to target resistance to cancer treatments -- JERUSALEM, Israel, BOTHELL, WA and VANCOUVER, Canada, Dec. 21 /PRNewswire-FirstCall/ - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced...

BOTHELL, WA and VANCOUVER, BC, Dec. 20 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will host a conference call at 8:30 a.m. Eastern Time on Monday, December 21, 2009. A live webcast will be available through the Investor Relations page of the OncoGenex Web site at http://ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 888-747-4649 (U.S. & Canada) or 913-312-1507 (International). A webcast...

Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time BOTHELL, WA and VANCOUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the third quarter and nine months ended September 30, 2009 and reviewed the Company's highlights for the third quarter of 2009. The following consolidated results reflect the operations of OncoGenex Technologies Inc. ("OncoGenex...

BOTHELL, WA and VANCOUVER Nov. 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will announce third quarter financial results after the market closes on Thursday, November 5, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. ET that afternoon to provide a business update and discuss the third quarter results. A live webcast will be available through the Events and Presentations Web page found in the Investor...

BOTHELL, WA, and VANCOUVER, Oct. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment. OncoGenex had previously received Fast Track Designation for second-line docetaxel treatment with OGX-011 in combination with...

BOTHELL, WA and VANCOUVER, Sept. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company will webcast presentations at the following investor conferences: - Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 at 12:30 p.m. Eastern Time in the Fahnestock Salon at the New York Palace Hotel in New York City. - Thomas Weisel Partners Healthcare Conference on Friday, September...